Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma

TheMotleyFool

0 0

3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma

Finally.

Gilead Sciences (NASDAQ: GILD) announced on Monday that it was acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Investors had long waited for the big biotech to make a deal. One analyst even wrote a letter to the company earlier this year urging it to move forward quickly with an acquisition.

Kite's shareholders have a lot to like about the deal, since the price tag represents a premium of nearly 30% to the small biotech's previous close. But what about Gilead's shareholders? Here are three reasons for investors to cheer Gilead's acquisition of Kite.

Source: Fool.com